Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1996-12-23
1998-09-01
LeGuyader, John L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
435 6, 435 9131, 4351723, 4353201, 435325, 536 231, 536 232, 536 245, C12Q 168, C12N 508, C70H 2102, A61R 4800
Patent
active
058011587
ABSTRACT:
An enzymatic RNA molecule which cleaves mRNA associated with development or maintenance of colon carcinoma.
REFERENCES:
patent: 4987071 (1991-01-01), Cech et al.
Chang and Miller, "Ras, an Inner Membrane Transducer of Growth Stimuli," in Prospect for Antisense Nucleic Acid Therapy of Cancer and AIDS, Wiley-Liss, Inc., pp. 115-124 (1991).
Holm et al., "Construction of a Ribozyme Catalytic Activity Against the mRNA of the Multidrug Resistance-Associated P-Glycoprotein," Proceedings of the 83rd Annual Meeting of the American Association for Cancer Research 33:401 at abstract No. 2393 (1992).
Kobayashi et al., "Cleavage of human MDR1 mRNA by a hammerhead ribozyme." FEBS Letters 319:71-74 (1993).
Stephenson and Gibson, "In Vitro Cleavage of an N-ras Messenger-Like RNA by a Ribozyme," Antisense Research & Development 1:261-268 (1991).
Barbacid, "ras Genes," Annu. Rev. Biochem. 56:779-827 (1987).
Bos, "ras Oncogenes in Human Cancer: A Review," Cancer Research 49:4682-4689 (1989).
Cech, "Ribozymes and Their Medical Implications," JAMA 260:3030-3034 (1988).
Guerrier-Takada et al., "The RNA Moiety of Ribonuclease P Is the Catalytic Subunit of the Enzyme," Cell 35:849-857 (1983).
Hampel et al., "RNA Catalyst for Cleaving Specific RNA Sequences," filed Sep. 20, 1989, which is a Contituation-in-Part of U.S. Ser. No. 07/247,100 filed Sep. 20, 1988.
Hampel et al., "Hairpins' Catalytic RNA Model: Evidence for Helices and Sequence Requirement for Substrate RNA," Nucleic Acids Research 18:299-304 (1990).
Hampel and Tritz, "RNA Catalytic Properties of the Minimum (-)sTRSV Sequence," Biochemistry 28:4929-4933 (1989).
Harrison's Priniciples of Internal Medicine vol. 1, pp. 374-380 and pp. 1116-1331, (Isselbacher et al. eds), McGraw-Hill, Inc. (1994).
Haseloff and Gerlach, "Simple RNA Enzymes with New Highly Specific Endoribonuclease Activities," Nature 334:585-591 (1988).
Kaskani-Sabet et al., "Reversal of the Maligmant Phenotype by an Anti-ras Ribozyme," Antisense Research & Development 2:3-15 (1992).
Jeffries and Symons, "A Catalytic 13-mer Ribozyme," Nucleic Acid Research 17:1371-1377 (1989).
Kim and Cech, "Three-dimensional model of the active site of the self-splicing rRNA precursor of Tetrahymena," Proc. Natl. Acad. Sci. USA 84:8788-8792 (1987).
Mamone et al., "Design of Mannerhead Ribozymes Targeted to Sequences in HIV, HSV, and the RAT ANF GENE," Abstract of Keystone, CO (May 27, 1992).
McGrath, et al., "Structure and organization of the human Ki-ras proto oncogene and a related processed pseudogene," Nature 304:501 (1981).
Oncogenes: An Introduction to the Concept of Cancer Genes pp. 182-197 (Burck et al. eds), Springer-Verlag, New York (1988).
Oncogenes, pp. 141-159, (Geoffrey M. Cooper, ed.), Jones and Bartless Publishers, Boston (1990).
Pavco et al., "Regulation of Self-Splicing Reactions by Antisense RNA," Abstract of Keystone, CO (May 27, 1992).
Perrotta and Been, "Cleavage of Oligoribonucleotides by a Ribozyme Derived from the Hepatitis .delta. Virus RNA Sequence," Biochemistry 31:16-21 (1992).
Rossi et al., "Ribozymes as Anti-HIV-1 Therapeutic Agents: Principles, Applications, and Problems," Aids Research and Human Retroviruses 8:183-189 (1992).
Sarver et al., "Ribozymes as Potential Anti-HIV-1 Therapeutic Agents" Science 247:1222-1225 (1990).
Tseng and Brown, "Antisense oligonucleotide technology in the development of cancer therapeutics," Cancer Gene Therapy 1:65-71 (1994).
Weerasinghe et al., "Resistance to Human Immunodeficiency Virus Type 1 (HIV-1) Infection in Human CD4.sup.+ Lymphocyte-Derived Cell Lines Conferred by Using Retriviral Vectors Expressing an HIV-1 RNA-Specific Ribozyme," Journal of Virology 65:5531-5534 (1994).
Gewistz et al. PNAS 93:3161-3163 (1996).
Stull et al. Pharm. Res. 12:465-483 (1995).
Rojanasakul Adv. Drug Delivery Rev. 18(1996):115-131.
Draper Kenneth G.
Thompson James D.
LeGuyader John L.
Ribozyme Pharmaceuticals Inc.
LandOfFree
Enzymatic RNA with activity to RAS does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enzymatic RNA with activity to RAS, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enzymatic RNA with activity to RAS will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-270361